the 14th Lu Daopei Hematology Forum | Professor Yuqian Sun: Precision Assessment, Tailored Strategies — Current Status and Future Directions of Hematopoietic Stem Cell Transplantation in Older Patients

the 14th Lu Daopei Hematology Forum | Professor Yuqian Sun: Precision Assessment, Tailored Strategies — Current Status and Future Directions of Hematopoietic Stem Cell Transplantation in Older Patients

Bringing together leading experts in Hebei and staying true to its mission for 14 years. On August 21, 2026,the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic experience, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across China gathered to discuss the development of the field, making the conference an important academic platform for advancing hematologic disease diagnosis and treatment in China. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Yuqian Sun of Peking University People's Hospital, who shared her expert insights on the current status of hematopoietic stem cell transplantation in older patients, as well as patient assessment and selection strategies.
the 14th Lu Daopei Hematology Forum | Professor Xingyu Cao: Precision Risk Stratification, Optimized Strategies — Advances and Strategies in Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes

the 14th Lu Daopei Hematology Forum | Professor Xingyu Cao: Precision Risk Stratification, Optimized Strategies — Advances and Strategies in Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes

Bringing together leading experts in Hebei and staying true to its mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic experience, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across China gathered to discuss the development of the field, making the conference an important academic platform for advancing hematologic disease diagnosis and treatment in China. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Xingyu Cao of Lu Daopei Hospital, who shared her expert insights on the role of transplantation in myelodysplastic syndromes (MDS), the timing of transplantation, advances in conditioning regimens, and strategies for preventing relapse.
Professor Zhang Xiaohui Elected Vice Chair-Elect of the Hematology Branch of the Chinese Medical Association

Professor Zhang Xiaohui Elected Vice Chair-Elect of the Hematology Branch of the Chinese Medical Association

On December 23, 2024, the Hematology Branch of the Chinese Medical Association held its committee transition meeting in Beijing, where the 12th Committee, consisting of 87 members, was elected. Following individual presentations and a secret ballot by all committee members, Professor Zhang Xiaohui, Deputy Director and Director of the Office of the National Clinical Research Center for Hematologic Diseases, Deputy Director of the Peking University Institute of Hematology, and Professor of Hematology at Peking University People's Hospital, was elected Vice Chair-Elect of the Hematology Branch. Professor Jiang Qian and Professor Chang Yingjun were also elected as committee members.
the 14th Lu Daopei Hematology Forum丨Professor Yuzhu Shi: Identifying Etiology Through Imaging for Precise Diagnosis — Imaging Diagnosis of Central Nervous System Infections After Hematopoietic Stem Cell Transplantation

the 14th Lu Daopei Hematology Forum丨Professor Yuzhu Shi: Identifying Etiology Through Imaging for Precise Diagnosis — Imaging Diagnosis of Central Nervous System Infections After Hematopoietic Stem Cell Transplantation

On August 21, 2026, the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Over the past 14 years, the conference has established a strong academic foundation. This year's meeting focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases, bringing together experts and scholars from across China to discuss advances in the field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Yuzhu Shi from Lu Daopei Hospital for an interview. He shared his insights into the pathogen characteristics of central nervous system (CNS) infections after hematopoietic stem cell transplantation (HSCT), key imaging features for differential diagnosis, and the clinical value and future development of imaging technologies.
2026 Pujiang Urological Oncology Conference丨Professor Gang Zhu: AI and Holographic Imaging Empower Urologic Oncology Surgery — From Precision Resection to Functional Preservation

2026 Pujiang Urological Oncology Conference丨Professor Gang Zhu: AI and Holographic Imaging Empower Urologic Oncology Surgery — From Precision Resection to Functional Preservation

The 2026 Pujiang Urological Oncology Conference was held in Shanghai, bringing together experts from China and abroad to discuss standardized diagnosis and treatment, innovations in surgical techniques, and advances in precision medicine in urologic oncology. At this year's conference, the application of artificial intelligence (AI) and holographic imaging (three-dimensional reconstruction) in robotic surgery emerged as a major focus. Oncology Frontier – UroStream invited Professor Gang Zhu of Beijing United Family Hospital for an interview to discuss the clinical value of AI and holographic imaging, strategies for functional preservation, and the translational challenges involved in moving innovative technologies from demonstration to routine clinical practice.
2026 Pujiang Urological Oncology Academic Conference丨Professor Dingwei Ye: Reshaping First-Line Treatment for Urothelial Carcinoma — Standardized Comprehensive Management to Maximize Long-Term Patient Benefit

2026 Pujiang Urological Oncology Academic Conference丨Professor Dingwei Ye: Reshaping First-Line Treatment for Urothelial Carcinoma — Standardized Comprehensive Management to Maximize Long-Term Patient Benefit

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai. In recent years, innovative approaches including antibody-drug conjugates (ADCs), immunotherapy, and precision diagnostics have developed rapidly, shifting the treatment goals of urothelial carcinoma from short-term disease control toward deeper responses, long-term survival, and comprehensive disease management. Enfortumab vedotin-based combination therapy has changed the first-line treatment standard for locally advanced or metastatic urothelial carcinoma (LA/mUC). At the same time, patient selection, standardized treatment, adverse event management, response assessment, and long-term follow-up in real-world practice have become critical to translating evidence-based benefits into meaningful clinical outcomes. Oncology Frontier · UroStream invited Professor Dingwei Ye of Fudan University Shanghai Cancer Center to share his clinical perspectives on first-line treatment transformation, standardized continuous treatment, and advances in perioperative research.
From Evidence to Clinical Practice丨FRUSICA-2 Case Series in Second-Line Treatment of Advanced Renal Cell Carcinoma Officially Released

From Evidence to Clinical Practice丨FRUSICA-2 Case Series in Second-Line Treatment of Advanced Renal Cell Carcinoma Officially Released

Building on the evidence from the pivotal FRUSICA-2 registration study, the FRUSICA-2 Case Series has now been officially launched. This case collection brings together real-world clinical cases from multiple centers across China, providing practical insights into the clinical application of fruquintinib plus sintilimab as second-line treatment for advanced renal cell carcinoma. Scan the QR code to access the complete case collection.
Professor Edmund Chiong: Advances in PARP Inhibitor Combination Therapy and Precision Application

Professor Edmund Chiong: Advances in PARP Inhibitor Combination Therapy and Precision Application

In recent years, with the continued advancement of precision medicine, PARP inhibitors have assumed an increasingly important role in prostate cancer treatment, particularly among patients harboring homologous recombination repair (HRR) gene alterations, in whom they have demonstrated clear clinical benefits. At the same time, a range of combination strategies involving PARP inhibitors and androgen receptor pathway inhibitors (ARPIs), immunotherapy, chemotherapy, and other treatment modalities have emerged, ushering advanced prostate cancer into an era of combination therapy. However, despite the rapid accumulation of clinical evidence, questions remain regarding the optimal treatment sequence, differences in benefit across specific HRR mutation subtypes, and strategies for managing resistance in the setting of combination therapy. Further evidence is needed to clarify these issues.
2026 Pujiang Urological Oncology Academic Conference丨Professor Shudong Zhang: Surgical Treatment and Multidisciplinary Management of UTUC with Inferior Vena Cava Tumor Thrombus — From Precise Imaging Assessment to Robotic Minimally Invasive Thrombectomy and Comprehensive Care

2026 Pujiang Urological Oncology Academic Conference丨Professor Shudong Zhang: Surgical Treatment and Multidisciplinary Management of UTUC with Inferior Vena Cava Tumor Thrombus — From Precise Imaging Assessment to Robotic Minimally Invasive Thrombectomy and Comprehensive Care

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai, bringing together experts in urological oncology from China and abroad to discuss standardized diagnosis and treatment, surgical innovation, and advances in precision medicine. Upper tract urothelial carcinoma (UTUC) complicated by inferior vena cava (IVC) tumor thrombus is relatively rare and is associated with substantially increased surgical complexity and perioperative risk. Oncology Frontier · UroStream invited Professor Shudong Zhang of Peking University Third Hospital for an interview, during which he shared his team's experience and clinical perspectives on preoperative imaging assessment and risk stratification, the application of robotic surgery, and multidisciplinary team (MDT) management throughout the treatment journey.
2026 Pujiang Urological Oncology Academic Conference丨Nan Liu: Precision Strategies for Robot-Assisted Partial Nephrectomy of Completely Endophytic Renal Tumors—from Preoperative 3D Planning to Intraoperative Localization and Nephron-Sparing Decision-Making

2026 Pujiang Urological Oncology Academic Conference丨Nan Liu: Precision Strategies for Robot-Assisted Partial Nephrectomy of Completely Endophytic Renal Tumors—from Preoperative 3D Planning to Intraoperative Localization and Nephron-Sparing Decision-Making

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai, bringing together experts from China and abroad to discuss standardized diagnosis and treatment, innovations in surgical techniques, and advances in precision medicine in urological oncology. Completely endophytic renal tumors are particularly challenging because they lack visible landmarks on the renal surface, making intraoperative localization, margin control, and preservation of the collecting system and renal vasculature difficult. Oncology Frontier – UroStream invited Professor Nan Liu of Chongqing University Cancer Hospital for an interview to discuss preoperative assessment, intraoperative localization and tumor resection strategies, and nephron-sparing decision-making for highly complex renal tumors, sharing his clinical experience and perspectives on surgical techniques.